Curated News
By: NewsRamp Editorial Staff
October 07, 2026
Quantum BioPharma Partners with Thermo Fisher for Phase 2 MS Trial
TLDR
- Quantum BioPharma's Lucid-MS, with Thermo Fisher, enters phase 2, offering a first-mover advantage in neuroprotective MS therapies.
- Lucid-MS targets demyelination by protecting nerve insulation, not just modulating the immune system, and begins rigorous phase 2 testing.
- Quantum BioPharma and Thermo Fisher advance a novel MS treatment that could restore nerve protection and improve lives.
- Quantum BioPharma's Lucid-MS takes a fresh angle on MS by shielding nerves, moving into phase 2 trials with Thermo Fisher.
Impact - Why it Matters
This news matters because it highlights a promising new approach to treating multiple sclerosis that goes beyond immune suppression to protect nerve fibers directly. If successful, Lucid-MS could offer a much-needed alternative for patients who don't respond to current therapies. The involvement of Thermo Fisher, a leader in clinical research, adds credibility and resources to the trial, increasing the chances of generating robust data. For investors, this partnership de-risks the development path and could accelerate Quantum BioPharma's timeline, potentially leading to a major breakthrough in MS treatment.
Summary
Most multiple sclerosis (MS) drugs work by quieting the immune system, but a new partnership is putting the spotlight on a different strategy: protecting the nerve’s own insulation. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific. The contract covers implementation of the phase 2 trial of Lucid-MS, Quantum’s lead drug candidate for MS.
Lucid-MS is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. This could represent a significant shift in MS treatment, as current therapies primarily focus on immune suppression. Thermo Fisher’s clinical research business, a leading global contract research organization, brings impressive expertise in central nervous system and MS studies, making it a strong partner to execute the rigorous clinical test. The agreement moves Lucid-MS from planning into execution, marking a critical step forward for Quantum BioPharma.
For investors and patients alike, this collaboration signals progress in developing a potentially transformative therapy for MS. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. Read More>>
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Partners with Thermo Fisher for Phase 2 MS Trial
